Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Amglidia (glibenclamide) for the Treatment of Neonatal Diabetes

Drug Name

Amglidia (glibenclamide)

Developer

Ammtek

Therapy Class

Sulphonylureas

Product Description

Second-generation, short half-life sulphonylurea

Current Indication

Neonatal diabetes mellitus

Market Sector

Diabetes

Development Status

Approved in Europe
Expand
Close
Close
Close

Go Top